Previous studies have indicated that SLC members were regulated by TGFβ1 (Kim et al., 2020), and a bispecific antibody of TGF-β and PD-L1 showed a potent and durable antitumor activity by normalizing tumor immune microenvironment and enhanced anti-tumor immune response. The gene discussed is TGFB1; the disease is neoplasm.